The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Ono to Provide University of Tokyo with Access to Its Compound Library
July 11, 2014
- Bayer Yakuhin Adopts Unique Certificate Program to Train Cancer Sales Reps
July 10, 2014
- Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
- LSI Medience Develops Cardiotoxicity Assessment System Using Myocardial iPS Cells in NEDO-Driven Research Project
July 10, 2014
- Apeiron Begins PI Study of Neuroblastoma Immunotherapy Agent in Japan
July 10, 2014
- Vital-Net Makes Miyagi-Based Dispensing Pharmacy Chain Ohno its Subsidiary
July 10, 2014
- Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
- MTPC to Up Japan Sales Force by 200-300 Partly via Job Transfers
July 9, 2014
- 31 Executives Received Annual Compensations for FY2013 of Over 100 Million Yen: Jiho Survey
July 9, 2014
- MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
- Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
- Sanofi’s Prostate Cancer Drug Cabazitaxel Gets Japan OK
July 7, 2014
- MTPC’s SGLT-2 Inhibitor Canaglu Wins Japan Approval
July 7, 2014
- European Commission Approves Expanded Indication for Halaven for Earlier Use in Breast Cancer Treatment: Eisai
July 7, 2014
- Nippon Kayaku Obtains Approval for Remicade Biosimilar
July 7, 2014
- Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
- Santen to Complete Acquisition of Ophthalmology Assets from Merck
July 4, 2014
- Taiho Submits Application for Additional Indication of Febrile Neutropenia for Zosyn
July 4, 2014
- BMKK Asks Major Law Firm to Conduct Independent Investigation of Clinical Research on Sprycel
July 4, 2014
- Kyowa Kirin to Resume Development of Bardoxolone Methyl for CKD Patients with Type 2 Diabetes
July 4, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…